Table 1.
Summary data for patient cohort
| Characteristics | HC | DC | AAV‐AP | AAV‐RP | ||
|---|---|---|---|---|---|---|
| No. | 10 | 14 | 17 | 21 | ||
| Age, median (range), years | 57 (45–68) | 65 (45–75) | 61 (27–81) | 60 (30–79) | ||
| Male/female | 5/5 | 9/5 | 9/8 | 13/8 | ||
| ANCA positivity, n (%) | Anti‐MPO | 0 | 0 | 8 (47·1) | 7 (47·6) | |
| Anti‐PR3 | 0 | 0 | 7 (41·2) | 8 (38·1) | ||
| Negative | 0 | 0 | 1 (5·9) | 2 (9·5) | ||
| Unknown | 0 | 0 | 1 (5·9) | 1 (4·8) | ||
| Diagnosis, n (median duration of follow‐up, month) | GPA | n.a. | n.a. | 8 (0) | 7 (86) | |
| MPA | n.a. | n.a. | 6 (0) | 8 (17) | ||
| EGPA | n.a. | n.a. | 3 (120) | 6 (62) | ||
| BVAS, median (range) | n.a. | n.a. | 14 (2–32) | 0 | ||
| CRP (mg/dl), median (IQR) | n.a. | 5 (3–23) | 18 (12·3–125) | 2 (1–5) | ||
| Creatinine (mmol/l), mean (s.e.m.) | n.a. | 179·5 (42·18) | 248·4 (71·3) | 177·2 (45·3) | ||
| eGFR (ml/min), mean (s.e.m.) | n.a. | 54·5 (9·5) | 60·2 (11·4) | 62·8 (8·3) | ||
| Immunosuppression treatment, n (%) | Treatment‐naive | Yes | Yes | 3 (18) | 0 | |
| Rituximab | 1–6 months | 0 | 0 | 1 (6) | 1 (5) | |
| > 6 months | 0 | 0 | 0 | 3 (14) | ||
| CYC | 1–6 months | 0 | 0 | 0 | 0 | |
| 6–12 months | 0 | 0 | 0 | 3 (14) | ||
| > 12 months | 0 | 0 | 2 (12) | 12 (57) | ||
| Aza | Current | 0 | 0 | 1 (6) | 8 (38) | |
| MMF | Current | 0 | 0 | 2 (12) | 2 (10) | |
| MTX | Current | n.a. | n.a. | 0 | 2 (10) | |
| Steroids | Current | n.a. | n.a. | 11 (65) | 11 (52) | |
Anti‐neutrophil cytoplasm autoantibody (ANCA)‐associated vasculitis (AAV)‐AP = AAV in active phase; AAV‐RP = AAV in remission phase; Aza = azathioprine; CRP = median C‐reactive protein; CYC = cyclophosphamide; DC = disease control; eGFR = estimated glomerular filtration rate; HC = healthy control; IQR = interquartile range; MMF = mycophenolate mofetil; MTX = methotrexate; MPA = microscopic polyangiitis; n.a. = not applicable; s.e.m.= standard error of the mean; MPO = myeloperoxidase; PR3 = proteinase‐3; BVAS = Birmingham Vasculitis Activity Score; GPA = granulomatosis with polyangiitis; EGPA = eosinophilic granulomatosis with polyangiitis.